Gary A. Lyons Joins HealthCare Royalty Partners Senior Advisor Board

STAMFORD, Conn. — October 23, 2018 — HealthCare Royalty Partners (“HCR"), a global healthcare investment firm, today announced the appointment of life sciences industry veteran Gary A. Lyons to the firm’s Senior Advisor Board.

“We are pleased to welcome Gary to our Senior Advisor Board and believe that his decades-long experience as a CEO and senior manager in the biopharmaceutical sector will benefit HCR in sourcing and evaluating potential products of interest, particularly on the West Coast which historically has been our largest market,” said Clarke B. Futch, Managing Partner at HCR.

Mr. Lyons has more than 35 years of industry experience, including as Chief Executive Officer of Neurocrine Biosciences, Inc., a position he held from 1993 through 2008.  Mr. Lyons remains on the Board of Directors of Neurocrine.  Prior to Neurocrine, Mr. Lyons held several senior management positions at Genentech, including Vice President of Business Development and Vice President of Sales.  While at Genentech, Mr. Lyons also served as a member of the company’s Executive Committee and was responsible for international licensing, acquisitions and partnering for Genentech’s Corporate Venture Program. Mr. Lyons currently serves on the Board of Directors of Vical, Inc., Cytori Therapeutics, Inc., and Novus Therapeutics and is the Chairman of the Board of Directors of both Rigel Pharmaceuticals, Inc. and Retrophin, Inc.  He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from the Kellogg School of Management at Northwestern University.

“I am excited to work with the HCR team and other members of the Senior Advisor Board as the firm seeks to make investments in innovative biopharmaceutical companies and medically necessary products," commented Mr. Lyons.

About HealthCare Royalty Partners

HCR is a private investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage life science assets. HCR has $3.7 billion in cumulative capital commitments with offices in Stamford (CT), San Francisco, Boston and London  For more information, visit